Skip to main content

Precision Medicine and the Role of NGS Technology in Myeloid Malignancies

From the 2021 Joint Annual Meeting (recorded 6/29/2021)
Presented by Ranjana Arora, MD, MPH

Myeloid malignancies are complex clonal diseases with vast genetic heterogeneity and vast clonal evolution with disease progression. Molecular profiling is important for diagnosis, treatment, risk stratification, and understanding the evolution of disease with time. These diseases often show more than one mutation, and the use of multigene next generation sequencing (NGS) panels is important in not only diagnosis but also in deciding the treatment and response to therapy with follow-up for measurable disease assessment.

At the conclusion of this presentation, participants will be able to:

  • Role of Precision Medicine in diagnosis and treatment of myeloid malignancies.
  • Clinical relevance and interpretation of next generation sequencing assay (NGS) in myeloid malignancies.
  • Role of NGS in monitoring disease and understanding clonal evolution of disease.

ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of General (Hematology) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

This Advanced-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.